Evolution of the clinical simulation approach to assess digital health technologies

Coronavirus 2019 (COVID-19) has catalysed digital transformation in the health space. However, it remains a challenge to generate timely and cost-effective evidence for technologies (DHTs) ensure their safety efficacy. Traditional methods, such as randomised controlled trials (RCTs), are ill-suited assessing DHTs reasons of speed, agility, cost context. Clinical simulation using high-fidelity synthetic patient cases is emerging promising yet underexplored method evaluate DHTs. It offers several advantages, including conducting remote multi-site testing at low cost, inclusion high-risk profiles that usually excluded from RCTs adaptability different local clinical settings. This article shares some insights studies conducted Institute Global Health Innovation (IGHI) Imperial College London describes evolution this approach well future opportunities.